Aptevo, Niowave form 50/50 radiopharmaceutical oncology collaboration

Aptevo Therapeutics, Inc.

Aptevo Therapeutics, Inc.

APVO

0.00
  • Aptevo entered a 50/50 strategic collaboration with Niowave to develop up to three radiopharmaceutical oncology programs.
  • Niowave made an at-the-market equity investment at closing, taking a 7.9% stake with potential to reach 19.99% via warrants and future buys.
  • Initial program targets Nectin-4 using Aptevo multispecific antibody assets paired with Niowave radioisotope supply, including Actinium-225.
  • Partnership expands Aptevo into radiopharmaceutical therapeutics, addressing isotope supply constraints through Niowave manufacturing and distribution capabilities.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief on May 27, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.